MedPath

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

Phase 3
Completed
Conditions
Enteric Hyperoxaluria
Interventions
Drug: Placebo
Registration Number
NCT03456830
Lead Sponsor
Allena Pharmaceuticals
Brief Summary

The purpose of this study is to determine the efficacy and safety of ALLN-177 in patients with enteric hyperoxaluria.

Detailed Description

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study. This study is designed to determine whether treatment with ALLN-177 for 28 days can reduce urinary oxalate excretion in patients with enteric hyperoxaluria and to evaluate the safety of ALLN-177 in this patient population compared to placebo.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
115
Inclusion Criteria
  1. Provided informed consent
  2. Age 18 or older
  3. History of hyperoxaluria secondary to a known underlying enteric disorder associated with malabsorption (e.g., bariatric surgery, Crohn's disease, short bowel syndrome, or other malabsorption syndrome)
  4. Urinary Oxalate ≥ 50mg/24h
Exclusion Criteria
  1. Acute renal failure or estimated glomerular filtration rate (eGFR) < 30mL/min/1.73 m2
  2. Unable or unwilling to discontinue Vitamin C supplementation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo capsule
ALLN-177ALLN-177ALLN-177 3,750 units per capsule
Primary Outcome Measures
NameTimeMethod
Percent change from baseline in 24-hour urinary oxalate excretion during Weeks 1-44 weeks

Efficacy will be assessed based on percent change from baseline to the mean of Weeks 1-4, derived from all 24-hour collections during Weeks 1-4 on treatment

Secondary Outcome Measures
NameTimeMethod
Proportion of subjects with a ≥ 20% reduction from Baseline in 24-hour urinary oxalate excretion during Weeks 1-44 weeks

Efficacy will be assessed based on proportion of subjects with ≥ 20% reduction from baseline to the mean of Weeks 1-4, derived from all 24-hour collections during Weeks 1-4 on treatment

Trial Locations

Locations (63)

Urology Centers of Alabama

🇺🇸

Birmingham, Alabama, United States

University of Alabama, Department of Urology

🇺🇸

Birmingham, Alabama, United States

Mayo Clinic Hospital

🇺🇸

Phoenix, Arizona, United States

Urological Associates of Southern Arizona

🇺🇸

Tucson, Arizona, United States

Applied Research Center of Arkansas

🇺🇸

Little Rock, Arkansas, United States

TROVARE Clinical Research

🇺🇸

Bakersfield, California, United States

Advanced Urology Institute

🇺🇸

Daytona Beach, Florida, United States

Mayo Clinic - Jacksonville

🇺🇸

Jacksonville, Florida, United States

Center for Advanced GI (CFAGI)

🇺🇸

Maitland, Florida, United States

South Medical Research Group, Inc.

🇺🇸

Miami, Florida, United States

Scroll for more (53 remaining)
Urology Centers of Alabama
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.